As science sheds light on the medicinal value of psychedelic compounds, it’s not too surprising that we’re beginning to see the entheogenic equivalent of CBD: psychedelics that don’t cause hallucinations. For example, at the end of last year, it was announced that chemists had created a non-hallucinogenic analogue of the psychedelic alkaloid ibogaine.
If non-hallucinogenic psychedelic medicines prove effective, they could be used for the treatment of ailments like PTSD, depression, anxiety, and addiction. By eliminating the need for supervised psychedelic sessions, this would radically reduce the amount of time spent before, during, and after treatments.
In their search for these medicines, scientists are using a device called psychLight to separate psychoactive compounds from non-psychoactive ones. This sensor emits a bright glow when it finds a hallucinogenic compound interacting with a serotonin receptor.
At the moment, researchers have their collective eye on a molecule called AAZ-A-154. When tested on mice, this compound was found to have antidepressive properties similar to those of hallucinogenic psychedelics. If AAZ-A-154 passes safety tests that are now under way, it will be tested on human volunteers.
Regardless of the outcome, it will be interesting to learn how much of the healing value of these compounds is strictly a neurochemical phenomenon, and how much of it is inseparable from the heart-opening, paradigm-shifting qualities of a profound psychedelic experience.